T 0479/24 of 15.01.2026
- European Case Law Identifier
- ECLI:EP:BA:2026:T047924.20260115
- Date of decision
- 15 January 2026
- Case number
- T 0479/24
- Petition for review of
- -
- Application number
- 18189607.7
- IPC class
- C07D 217/26
- Language of proceedings
- English
- Distribution
- No distribution (D)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- CRYSTALLINE FORMS OF A PROLYL HYDROXYLASE INHIBITOR
- Applicant name
- Fibrogen, Inc.
- Opponent name
- Sandoz AG
Teva Pharmaceutical Industries Ltd
Generics [UK] Limited - Board
- 3.3.02
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 100(c)European Patent Convention Art 54European Patent Convention Art 56
- Keywords
- Grounds for opposition - amendments
Novelty
Inventive step - Catchword
- -
- Citing cases
- -
Order
For these reasons it is decided that:
The appeals are dismissed.